Details
Stereochemistry | RACEMIC |
Molecular Formula | C17H20ClNO |
Molecular Weight | 289.8 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCC(O)(C1=CC=CC=C1)C2=C(Cl)C=CC=C2
InChI
InChIKey=WRCHFMBCVFFYEQ-UHFFFAOYSA-N
InChI=1S/C17H20ClNO/c1-19(2)13-12-17(20,14-8-4-3-5-9-14)15-10-6-7-11-16(15)18/h3-11,20H,12-13H2,1-2H3
DescriptionSources: https://www.drugbank.ca/drugs/DB04837Curator's Comment: description was created based on several sources, including
http://www.hmdb.ca/metabolites/HMDB15585 |
https://www.ncbi.nlm.nih.gov/pubmed/24671376
Sources: https://www.drugbank.ca/drugs/DB04837
Curator's Comment: description was created based on several sources, including
http://www.hmdb.ca/metabolites/HMDB15585 |
https://www.ncbi.nlm.nih.gov/pubmed/24671376
Chlophedianol (Clofedanol) is a centrally-acting cough suppressant, although the mechanism of action is not known. It is available in Canada under the trade name Ulone. It is not available in the United States. Chlophedianol (Clofedanol) suppresses the cough reflex by a direct effect on the cough center in the medulla of the brain. It also has local anesthetic and antihistamine properties, and may have anticholinergic effects at high doses.
CNS Activity
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.drugs.com/mmx/ulone.html |
Primary | ULONE Approved UseIndicated for the symptomatic relief of nonproductive cough. Chlophedianol is used to provide relief of acute cough due to minor throat and bronchial irritation occurring with colds or inhaled irritants. |
Doses
Dose | Population | Adverse events |
---|---|---|
20 mg 3 times / day steady, oral Recommended Dose: 20 mg, 3 times / day Route: oral Route: steady Dose: 20 mg, 3 times / day Sources: |
healthy, adult n = 12 Health Status: healthy Condition: cough Age Group: adult Sex: unknown Population Size: 12 Sources: |
Disc. AE: Allergic rash... AEs leading to discontinuation/dose reduction: Allergic rash (1 patient) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Allergic rash | 1 patient Disc. AE |
20 mg 3 times / day steady, oral Recommended Dose: 20 mg, 3 times / day Route: oral Route: steady Dose: 20 mg, 3 times / day Sources: |
healthy, adult n = 12 Health Status: healthy Condition: cough Age Group: adult Sex: unknown Population Size: 12 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/604421/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/604421/ |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Chlophedianol Hydrochloride: A New Antitussive Agent. | 1960 Dec 17 |
|
Clinical evaluation of chlophedianol a new nonnarcotic antitussive. | 1962 Sep |
|
A comparative randomized double-blind clinical trial of isoaminile citrate and chlophedianol hydrochloride as antitussive agents. | 1982 Aug |
|
[Controlled double-blind study on the efficacy of clofedanol-sobrerol in the treatment of pediatric pertussis]. | 1984 Dec 31 |
|
Therapeutic options for acute cough due to upper respiratory infections in children. | 2012 Feb |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/mmx/ulone.html
Usual adult and adolescent dose is 25 mg every six to eight hours as needed.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6865909
The inhibition of specific binding of [3H]dextromethorphan (4 nM) to guinea pig brain homogenate was determined. Chlophedianol, a phenylalkylamine, had an IC value of 1300 nM.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
R05DB10
Created by
admin on Fri Dec 15 16:33:29 GMT 2023 , Edited by admin on Fri Dec 15 16:33:29 GMT 2023
|
||
|
WHO-VATC |
QR05DB10
Created by
admin on Fri Dec 15 16:33:29 GMT 2023 , Edited by admin on Fri Dec 15 16:33:29 GMT 2023
|
||
|
NCI_THESAURUS |
C66880
Created by
admin on Fri Dec 15 16:33:29 GMT 2023 , Edited by admin on Fri Dec 15 16:33:29 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB06695MIG
Created by
admin on Fri Dec 15 16:33:29 GMT 2023 , Edited by admin on Fri Dec 15 16:33:29 GMT 2023
|
PRIMARY | |||
|
7324
Created by
admin on Fri Dec 15 16:33:29 GMT 2023 , Edited by admin on Fri Dec 15 16:33:29 GMT 2023
|
PRIMARY | |||
|
DTXSID4022789
Created by
admin on Fri Dec 15 16:33:29 GMT 2023 , Edited by admin on Fri Dec 15 16:33:29 GMT 2023
|
PRIMARY | |||
|
135207
Created by
admin on Fri Dec 15 16:33:29 GMT 2023 , Edited by admin on Fri Dec 15 16:33:29 GMT 2023
|
PRIMARY | |||
|
C010432
Created by
admin on Fri Dec 15 16:33:29 GMT 2023 , Edited by admin on Fri Dec 15 16:33:29 GMT 2023
|
PRIMARY | |||
|
585
Created by
admin on Fri Dec 15 16:33:29 GMT 2023 , Edited by admin on Fri Dec 15 16:33:29 GMT 2023
|
PRIMARY | |||
|
42C50P12AP
Created by
admin on Fri Dec 15 16:33:29 GMT 2023 , Edited by admin on Fri Dec 15 16:33:29 GMT 2023
|
PRIMARY | |||
|
C73183
Created by
admin on Fri Dec 15 16:33:29 GMT 2023 , Edited by admin on Fri Dec 15 16:33:29 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201313
Created by
admin on Fri Dec 15 16:33:29 GMT 2023 , Edited by admin on Fri Dec 15 16:33:29 GMT 2023
|
PRIMARY | |||
|
21254
Created by
admin on Fri Dec 15 16:33:29 GMT 2023 , Edited by admin on Fri Dec 15 16:33:29 GMT 2023
|
PRIMARY | RxNorm | ||
|
2795
Created by
admin on Fri Dec 15 16:33:29 GMT 2023 , Edited by admin on Fri Dec 15 16:33:29 GMT 2023
|
PRIMARY | |||
|
42C50P12AP
Created by
admin on Fri Dec 15 16:33:29 GMT 2023 , Edited by admin on Fri Dec 15 16:33:29 GMT 2023
|
PRIMARY | |||
|
1135
Created by
admin on Fri Dec 15 16:33:29 GMT 2023 , Edited by admin on Fri Dec 15 16:33:29 GMT 2023
|
PRIMARY | |||
|
212-340-9
Created by
admin on Fri Dec 15 16:33:29 GMT 2023 , Edited by admin on Fri Dec 15 16:33:29 GMT 2023
|
PRIMARY | |||
|
100000085230
Created by
admin on Fri Dec 15 16:33:29 GMT 2023 , Edited by admin on Fri Dec 15 16:33:29 GMT 2023
|
PRIMARY | |||
|
CLOFEDANOL
Created by
admin on Fri Dec 15 16:33:29 GMT 2023 , Edited by admin on Fri Dec 15 16:33:29 GMT 2023
|
PRIMARY | |||
|
DB04837
Created by
admin on Fri Dec 15 16:33:29 GMT 2023 , Edited by admin on Fri Dec 15 16:33:29 GMT 2023
|
PRIMARY | |||
|
113595
Created by
admin on Fri Dec 15 16:33:29 GMT 2023 , Edited by admin on Fri Dec 15 16:33:29 GMT 2023
|
PRIMARY | |||
|
791-35-5
Created by
admin on Fri Dec 15 16:33:29 GMT 2023 , Edited by admin on Fri Dec 15 16:33:29 GMT 2023
|
PRIMARY | |||
|
m3336
Created by
admin on Fri Dec 15 16:33:29 GMT 2023 , Edited by admin on Fri Dec 15 16:33:29 GMT 2023
|
PRIMARY | Merck Index |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)